Moleculin Biotech, Inc. (MBRX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Moleculin Biotech, Inc. (MBRX) Healthcare & Pipeline Overview

Moleculin Biotech, Inc. is a clinical-stage biotechnology firm focused on developing novel drug candidates for challenging indications, including relapsed/refractory acute myeloid leukemia, brain tumors, and certain viral infections. Leveraging a pipeline of immune/transcription modulators and anthracyclines, the company addresses significant unmet medical needs within oncology and virology.

What Is the Investment Thesis for MBRX?

Moleculin Biotech, Inc. presents a research focus on developing novel drug candidates for highly resistant tumors and viruses, addressing significant unmet medical needs. The company's lead candidate, Annamycin, in Phase 1/2 studies for relapsed or refractory acute myeloid leukemia (AML) and lung metastases, represents a key value driver. Successful progression through these clinical stages could validate its therapeutic potential and attract further investment or partnership opportunities. Additionally, the immune/transcription modulator WP1066, in Phase I for brain tumors and pancreatic cancer, broadens the pipeline's scope into other challenging oncology indications. The company's strategic partnerships with institutions like MD Anderson provide credibility and access to expertise. However, as a clinical-stage biopharmaceutical company with a market capitalization of $3.15M and a small employee base of 17, MBRX faces substantial funding and clinical trial execution risks. Future financing activities and the outcomes of ongoing clinical trials are critical determinants of the company's trajectory, requiring close monitoring by institutional investors.

Based on FMP financials and quantitative analysis

MBRX Key Highlights

Clinical-stage pipeline focused on highly resistant tumors and viruses, addressing significant unmet medical needs.

• Lead drug candidate, Annamycin, is currently in Phase 1/2 studies for relapsed or refractory acute myeloid leukemia (AML) and lung metastases.
• Flagship immune/transcription modulator, WP1066, is in a Phase I clinical trial for brain tumors, pediatric brain tumors, and pancreatic cancer.
• Strategic partnership and collaboration agreements are in place with entities such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o.
• The company operates with a Beta of 1.74, indicating higher volatility relative to the broader market, typical for clinical-stage biotechnology firms.

Who Are MBRX's Competitors?

MBRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MBRX's Key Strengths?

Focused pipeline addressing high unmet medical needs in resistant tumors and viruses.

• Lead candidate Annamycin in Phase 1/2 studies for AML and lung metastases.
• Diverse pipeline including immune/transcription modulators for various cancers and viral indications.
• Strategic partnerships with reputable institutions like MD Anderson.

What Are MBRX's Weaknesses?

Clinical-stage company with no commercialized products and no current revenue generation.

• Significant reliance on external funding to finance ongoing R&D and clinical trials.
• Small market capitalization ($0.00B) and limited employee base (17), indicating early-stage development.
• High beta (1.74) suggests elevated stock price volatility and market risk.

What Could Drive MBRX Stock Higher?

MBRX catalyst: Anticipated data readouts from the ongoing Phase 1/2 studies of Annamycin for relapsed or refractory acute myeloid leukemia (AML) and lung metastases.

• Potential initiation or progression of later-stage clinical trials for Annamycin, contingent on positive Phase 1/2 results.
• Publication of initial data or progress reports from the Phase I clinical trial of WP1066 for brain tumors, pediatric brain tumors, and pancreatic cancer.
• Continued development and preclinical/clinical advancement of WP1220 for cutaneous T-cell lymphoma and WP1122 for glioblastoma multiforme and COVID-19.
• Potential announcements regarding new or expanded strategic partnerships and collaborations that could provide funding or accelerate development.

What Are the Key Risks for MBRX?

Financial-distress signal — its Altman Z-Score of -19.60 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• **Clinical Trial Failure Risk:** The primary risk for Moleculin Biotech is the inherent uncertainty of clinical trials. Drug candidates like Annamycin and WP1066 may fail to demonstrate efficacy or safety in ongoing or future clinical stages, leading to significant delays or complete termination of development programs.
• **Funding and Liquidity Risk:** As a clinical-stage company with no commercialized products, Moleculin Biotech is highly dependent on securing additional financing to fund its extensive research and development activities and clinical trials. Inability to raise sufficient capital could impede pipeline progression or necessitate scaling back operations.
• **Regulatory Approval Risk:** Even with positive clinical data, there is no guarantee that Moleculin's drug candidates will receive regulatory approval from agencies like the FDA. The approval process is rigorous and can be subject to unforeseen delays, additional data requests, or outright rejection.
• **Competitive Landscape Risk:** The biotechnology sector, particularly in oncology, is highly competitive. Larger pharmaceutical companies and other biotech firms are also developing treatments for similar indications, which could lead to market saturation or superior alternative therapies emerging.
• **Intellectual Property Risk:** The company's success relies on its ability to protect its proprietary drug candidates through patents. Challenges to its intellectual property, or the expiration of key patents, could undermine its competitive position and future revenue potential.

What Are the Growth Opportunities for MBRX?

• **Advancement of Annamycin in AML and Lung Metastases:** Annamycin, currently in Phase 1/2 studies for relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs, represents a significant growth opportunity. The global AML market is projected to reach substantial valuations, driven by the need for more effective therapies in resistant populations. Successful progression through clinical trials, particularly demonstrating improved efficacy or safety profiles compared to existing treatments, could unlock a considerable market share. The timeline for this opportunity extends over several years, contingent on trial outcomes, regulatory approvals, and potential commercialization partnerships.
• **Expansion of WP1066 into Brain Tumors and Pancreatic Cancer:** WP1066, an immune/transcription modulator in Phase I clinical trials for brain tumors (including pediatric) and pancreatic cancer, targets highly aggressive and difficult-to-treat malignancies with poor prognoses. The markets for glioblastoma and pancreatic cancer therapies are substantial, with significant unmet needs for novel, effective treatments. Positive data from ongoing and future clinical trials could position WP1066 as a promising candidate, potentially leading to accelerated development pathways given the severity of these diseases. This opportunity has a long-term horizon, dependent on clinical success and regulatory milestones.
• **Development of WP1220 for Cutaneous T-cell Lymphoma (CTCL):** WP1220, an analog of WP1066 designed for topical treatment of cutaneous T-cell lymphoma, addresses a niche but persistent dermatological cancer. The market for CTCL treatments, while smaller than major oncology indications, still represents a valuable segment, particularly for therapies that offer improved patient convenience or reduced systemic side effects. Successful development of a topical formulation could differentiate WP1220 from existing systemic treatments, offering a targeted approach with potentially fewer adverse events. The timeline for this opportunity is tied to clinical development and regulatory approval for a specialized indication.
• **Potential of WP1122 for Glioblastoma and COVID-19:** WP1122, another compound in Moleculin's pipeline, is being developed for glioblastoma multiforme and COVID-19. Glioblastoma remains an area of high unmet need, and any effective new therapy would be highly valued. Furthermore, the ongoing global need for antiviral treatments, particularly for emerging variants or in immunocompromised populations, presents a dynamic market opportunity. Demonstrating efficacy in either or both of these distinct indications could significantly broaden the company's market reach and revenue potential, albeit with varying timelines and regulatory pathways for each.
• **Leveraging Strategic Partnerships for Pipeline Advancement:** Moleculin Biotech's collaboration agreements with institutions like MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. represent a critical growth opportunity. These partnerships can provide access to advanced research facilities, clinical trial expertise, and potential co-development or licensing opportunities. Such collaborations can accelerate drug development, de-risk clinical programs, and potentially provide non-dilutive funding or future commercialization pathways, enhancing the company's ability to bring its drug candidates to market more efficiently. This ongoing opportunity is crucial for a small clinical-stage company.

What Are MBRX's Competitive Advantages?

• Proprietary drug candidates with unique mechanisms of action targeting specific disease pathways in highly resistant cancers and viruses.
• Intellectual property protection (patents) for its lead compounds like Annamycin, WP1066, WP1220, and WP1122, providing market exclusivity upon approval.
• Specialized focus on difficult-to-treat diseases with high unmet medical needs, potentially leading to faster regulatory pathways or orphan drug designations.
• Strategic collaborations with renowned research institutions such as MD Anderson, offering access to expertise, resources, and clinical trial infrastructure.
• Accumulated clinical trial data and scientific knowledge specific to its pipeline, creating a barrier to entry for new competitors.

What Does MBRX Do?

Moleculin Biotech, Inc., established in 2015 and headquartered in Houston, Texas, operates as a clinical-stage pharmaceutical company dedicated to the discovery and development of innovative drug candidates targeting highly resistant tumors and viruses. The company's strategic focus is on addressing severe medical conditions where existing treatments are often inadequate, thereby aiming to fulfill significant unmet medical needs. Its foundational approach involves advancing a pipeline of proprietary molecules through various stages of clinical development. The cornerstone of Moleculin's pipeline is Annamycin, an anthracycline currently undergoing Phase 1/2 clinical studies. Annamycin is being investigated for its potential efficacy in treating relapsed or refractory acute myeloid leukemia (AML), a particularly aggressive blood cancer, and cancers that have metastasized to the lungs. This drug candidate represents a critical component of the company's oncology strategy, targeting difficult-to-treat cancer types. Beyond Annamycin, Moleculin Biotech is also developing a suite of immune/transcription modulators. Its flagship compound in this category is WP1066, which is in a Phase I clinical trial. WP1066 is being evaluated for the treatment of various challenging malignancies, including brain tumors, pediatric brain tumors, and pancreatic cancer. The company's portfolio further extends to WP1220, an analog of WP1066, designed for the topical treatment of cutaneous T-cell lymphoma. Additionally, WP1122 is under development for glioblastoma multiforme, a highly aggressive form of brain cancer, and has also shown potential for treating COVID-19. Moleculin Biotech actively fosters strategic collaborations and partnership agreements to advance its research and development initiatives. Notable partners include MD Anderson, a globally recognized cancer center, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. These collaborations are instrumental in supporting the company's clinical programs and expanding its scientific reach. With a lean operational structure, employing 17 individuals, Moleculin Biotech maintains a concentrated effort on its specialized drug development programs, positioning itself within the competitive biotechnology landscape as a focused innovator in difficult-to-treat diseases.

What Products and Services Does MBRX Offer?

• Develops drug candidates for highly resistant tumors and viruses.
• Advances Annamycin, a lead drug candidate, for relapsed or refractory acute myeloid leukemia (AML) and lung metastases.
• Researches WP1066, an immune/transcription modulator, for brain tumors, pediatric brain tumors, and pancreatic cancer.
• Develops WP1220, an analog of WP1066, for the topical treatment of cutaneous T-cell lymphoma.
• Explores WP1122 for glioblastoma multiforme and COVID-19 treatment.
• Conducts preclinical and clinical-stage research and development of pharmaceutical compounds.
• Engages in strategic partnerships with research institutions and other pharmaceutical companies.

How Does MBRX Make Money?

• Focuses on the research and development of proprietary drug candidates for high-unmet-need diseases.
• Aims to generate future revenue through the successful commercialization (either directly or via licensing agreements) of its drug candidates following regulatory approval.
• Currently operates as a clinical-stage company, meaning it does not have commercialized products generating significant revenue.
• Relies on external funding sources, such as equity financing, grants, and potentially future milestone payments from partnerships, to finance its ongoing clinical trials and R&D activities.
• Seeks to create value through intellectual property protection of its drug candidates and their potential market exclusivity.

What Industry Does MBRX Operate In?

Moleculin Biotech, Inc. operates within the highly specialized and competitive biotechnology industry, specifically focusing on oncology and virology. This sector is characterized by extensive research and development cycles, significant capital requirements, and stringent regulatory pathways. The broader biotechnology market is driven by advancements in genomic research, personalized medicine, and the increasing global demand for innovative therapies for complex diseases. Moleculin's focus on "highly resistant tumors and viruses" places it within a niche addressing critical unmet medical needs, which can command premium pricing upon successful commercialization. However, as a clinical-stage company, MBRX faces intense competition from larger pharmaceutical companies with established pipelines and greater financial resources, as well as numerous other smaller biotech firms vying for similar indications. The industry is also subject to rapid scientific breakthroughs and shifts in treatment paradigms, necessitating continuous innovation and adaptability.

Who Are MBRX's Key Customers?

• Future patients suffering from relapsed or refractory acute myeloid leukemia, brain tumors, pancreatic cancer, cutaneous T-cell lymphoma, glioblastoma multiforme, and viral infections like COVID-19.
• Oncologists, hematologists, neurologists, dermatologists, and other healthcare providers who would prescribe the company's approved therapies.
• Potential pharmaceutical partners interested in licensing or co-developing specific drug candidates for broader market reach or specific indications.
• Healthcare systems and payers who would include approved therapies in their formularies.

Moleculin Biotech, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -19.60 places it in the distress zone, a signal of elevated financial risk.

Moleculin Biotech, Inc. (MBRX) Valuation Context

Valued at $3.15M, MBRX is classified as a micro-cap stock. Relative to its peer group, MBRX's quantitative score of 27/100 is below the peer average of 76/100.

Company Profile

Moleculin Biotech, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Houston, US. The company is led by CEO Walter V. Klemp. MBRX has traded publicly since 2016.

Wall Street analysts project Moleculin Biotech, Inc. revenue of about $71.4M for fiscal 2026, with EPS near $-5.32. The estimate reflects 3 contributing analysts.

Over the past six months, Moleculin Biotech, Inc. insiders filed 15 SEC Form 4 transactions — 6 sales and 9 purchases. On net that is roughly 4.0M shares acquired (about $750K) — insiders putting money in tends to read as conviction.

MBRX Financials

MBRX Latest News

MBRX Analyst Consensus

MBRX MoonshotScore

Moleculin Biotech, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources